logo

RDY

Dr. Reddy'S Laboratories·NYSE
--
--(--)
--
--(--)
8.50 / 10
Outperform

Fundamental measurement shows outstanding quality (8.5/10). Constructive metrics include Interest coverage ratio (EBIT / Interest expense) (%) and Revenue-MV, while concerns exist in Days sales outstanding. Final assessment: superior.

Fundamental(8.5)SentimentTechnical

Analysis Checks(9/10)

Revenue-MV
Value-0.12
Score3/3
Weight15.90%
1M Return10.54%
Total operating revenue (YoY growth rate %)
Value16.61
Score2/3
Weight1.36%
1M Return1.11%
Days sales outstanding
Value94.40
Score0/3
Weight-5.62%
1M Return-5.18%
Profit-MV
Value5.20
Score3/3
Weight15.28%
1M Return9.28%
Net income-Revenue
Value0.45
Score3/3
Weight15.08%
1M Return9.29%
PB-ROE
Value0.93
Score3/3
Weight17.19%
1M Return12.83%
Interest coverage ratio (EBIT / Interest expense) (%)
Value42.48
Score2/3
Weight-1.27%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value16.61
Score2/3
Weight0.52%
1M Return0.43%
Asset-MV
Value-0.60
Score3/3
Weight23.51%
1M Return13.15%
Cash-MV
Value0.02
Score3/3
Weight18.04%
1M Return9.67%
Is RDY undervalued or overvalued?
  • RDY scores 8.50/10 on fundamentals and holds a Discounted valuation at present. Backed by its 11.40% ROE, 16.26% net margin, 18.37 P/E ratio, 2.81 P/B ratio, and 1.47% earnings growth, these metrics solidify its Outperform investment rating.